Pittsburgh, United States
Generian is a healthcare and pharmaceutical startup based in the United States founded in 2019. The company focuses on revolutionizing small molecule therapeutics with the aim of addressing the limitations of biologics and improving the patient experience. Generian's unique drug discovery approach allows it to screen proteins of interest in their native cellular environment, enabling the discovery of small molecules against previously challenging drug protein targets.
Generian has internal programs for clinically validated targets, including FcRn and IL-4r alpha. In addition, the company has established research collaborations, such as the one with Astellas, to focus on novel targets. This diversified pipeline positions Generian as a potential game-changer in the pharmaceutical industry, with the ability to efficiently progress candidates through highly translational phenotypic screening.
Currently, there is no publicly disclosed information regarding Generian's last investment or the involved investors. For those interested in discovering more about Generian and its innovative approach to small molecule therapeutics, the company suggests reaching out to their team at [email protected].
